Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer
NCT ID NCT03930498
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer that cannot be surgically removed. Researchers are measuring survival, tumor response, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD-1 antibody (toripalimab) plus chemotherapy (cisplatin and gemcitabine) and radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option for people with recurrent nasopharyngeal cancer that is hard to treat.
What could go wrong
This is a small, early-phase trial with no comparison group, so results may not be definitive. Side effects from the combination therapy could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China